Capsugel, a provider of dosage form solutions to the pharmaceutical and related healthcare industries, today announced it will be presenting its innovative drug delivery technologies at the 2010 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, Louisiana, USA November 14th-18th.
Capsugel will feature its Product Development Centers where clients can have lipid-based or powder-filled capsule products developed using Capsugel’s proprietary liquid filling and powder dosing equipment, including Capsugel’s unique Xcelodose® S precision powder micro dosing system and the new CFS 1500 C Containment liquid filling and sealing system. This equipment together with the expertise of Capsugel’s scientists and commercial production capabilities offers clients the ability to use Capsugel for every phase of product development right through to commercial manufacturing.
Capsugel will also highlight the following technologies:
• Capsules for use in dry powder inhalers (DPIs) with experts on hand to discuss how its capsule design has been adapted to optimize puncturing and retraction behaviour, which can be critical in helping deliver the correct dose from a DPI.
• Vcaps Plus capsules, its new generation of hypromellose-based two piece capsules, optimizing drug delivery through immediate release of active pharmaceutical ingredients (APIs), and providing pH-independent dissolution. It is well suited for hygroscopic compounds, as well as formulations that include materials that are moisture sensitive or chemically unstable, and is suitable for patients that prefer vegetarian capsules for ethical or cultural reasons.
• The unique Xcelodose S precision powder micro dosing system, which can precisely dispense powder weights as low as 100μg and up to 100mg with a typical RSD of ~2%, and the new CFS 1500 C Containment liquid filling and sealing system will both be on display with live demonstrations available.
Capsugel’s experts will also be discussing the four posters it has on show. One poster demonstrates how Capsugel’s Licaps Drug Delivery System was used to enhance oral bioavailability of MP-470, a multi-targeted tyrosine kinase inhibitor developed by a US pharmaceutical firm specializing in novel cancer therapies. The poster details how a lipid based formulation of MP-470, was identified in 12 weeks, allowing the clinical stage manufacturing as a Licaps Drug Delivery System and dosing to be completed in an additional 14 weeks.
Another poster discusses how the Licaps Drug Delivery System was used to encapsulate a formulation for treatment of gastro-intestinal diseases in just eight weeks. This allowed the rapid production of a clinical batch for a Singapore-based drug development company to use in proof-of-concept trials.
“We are delighted to be sharing our ready-to-use solutions for producing both powder and liquid filled capsules, as well as having posters presented at this prestigious show,” said Keith Hutchison, Vice President of R&D at Capsugel. “We’ll showcase the cGMP capabilities of our Product Development Centers but also demonstrate that using our innovative drug delivery technologies can provide new formulations for use in first-in-human trials to be delivered in a short timeframe. We are also looking forward to meeting scientists who want to significantly improve oral bioavailability of their compounds or have to realize a challenging drug development deadline to discuss how Licaps Drug Delivery System can help them rapidly produce the optimum formulation for their initial clinical studies.”
Capsugel
www.capsugel.com
